uniQure N.V.
Company Snapshot
Company Overview
UniQure N.V. is a biopharmaceutical company dedicated to advancing gene therapies for patients with critical medical needs, particularly in developing adeno-associated virus (AAV)-based treatments. The company maintains a pipeline of investigational gene therapies aimed at addressing genetic disorders such as hemophilia B and Huntington's disease.
In 2021, UniQure and CSL Behring concluded a licensing agreement, granting CSL exclusive global rights to commercialize Hemgenix. UniQure retains responsibility for the global manufacturing of Hemgenix at its facility in Lexington, Mass. The agreement involved CSL making payments totaling $500 million to UniQure. In May 2023, UniQure sold a portion of the royalty rights from CSL's net sales of Hemgenix to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million in cash.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- Gene Therapies : The company provides adeno-associated virus (AAV)- based gene therapies utilizing its gene technology platform and delivers treatments to patients with severe genetic diseases and other complicated diseases.
Applications/End User Industries
- Biopharmaceuticals
- Biotechnology
